A cannabinoid-inspired compound takes aim at drug-resistant bacteria
Total Synthesis and Antibacterial Evaluation of (-)- and (+)-epi-Perrottetinene.
AI Summary
Drug-resistant Staphylococcus aureus, including MRSA, is becoming harder to treat, creating a need for new antibacterial compounds. This study developed an efficient, scalable synthesis of epi-perrottetinene (epi-PET), an unnatural bibenzyl-based cannabinoid analog inspired by the liverwort compound perrottetinene. Researchers produced both Δ8- and Δ9-epi-PET isomers and tested them against several bacterial targets.
The lead compound, E, showed strong activity against drug-sensitive and drug-resistant S. aureus, including MRSA clinical isolates, with MIC values of ≤ 1.2 μg/mL. It also remained active against bacteria with increased efflux-pump activity, bacterial biofilms, and bacteria living inside cells. In the reported laboratory tests, compound E caused low red-blood-cell damage (3.4% hemolysis) and minimal toxicity toward the mammalian cell lines examined. The findings suggest that epi-perrottetinene works partly by disrupting bacterial membranes and could serve as a promising starting point for future antibacterial drug development—but the abstract does not report clinical testing in people or evidence that cannabis products treat infections.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
Meta-analysis finds shared endocannabinoid gene changes across myopathies
Small biomarker analysis finds no significant changes after 10 HBOT sessions
Rat study finds mixed behavioral and biological effects of WIN under chronic…
Explore More Research
Stay informed about the latest cannabis science.